| Dr Sarayna Mcguire, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Dr Sarayna Mcguire |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972063154 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 30060 (Minnesota) | Secondary |
| 207P00000X | Emergency Medicine | 67776 (Minnesota) | Primary |
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.
A new study suggests that disturbed sleep in adolescents is associated with more symptoms of depression and greater uncertainly about future success. However, perceived support and acceptance from parents and teachers appears to have a protective effect.
Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.
The Supreme Court heard arguments yesterday in a case which pits brand name and generic drug manufacturers against the Federal Trade Commission.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.
A new study suggests that disturbed sleep in adolescents is associated with more symptoms of depression and greater uncertainly about future success. However, perceived support and acceptance from parents and teachers appears to have a protective effect.
Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.
The Supreme Court heard arguments yesterday in a case which pits brand name and generic drug manufacturers against the Federal Trade Commission.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sarayna Mcguire, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Dr Sarayna Mcguire, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.
A new study suggests that disturbed sleep in adolescents is associated with more symptoms of depression and greater uncertainly about future success. However, perceived support and acceptance from parents and teachers appears to have a protective effect.
Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.
The Supreme Court heard arguments yesterday in a case which pits brand name and generic drug manufacturers against the Federal Trade Commission.
› Verified 1 days ago
Dr. Sara Ann Schroeder Hevesi, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
David W Claypool, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Fernanda Bellolio, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Kristofer William Roberts, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jonathan F. Thomas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Jessica Stanich, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Bergthor Steinn Jonsson, CAND.MED. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |